{"groups":[{"description":"Participants with non-clear cell Renal Cell Carcinoma (nccRCC) received 400 mg Pembrolizumab (Pembro) intravenously (IV) on Day 1 of a 42-day cycle (every 6 weeks (Q6W)) for approximately 2 years PLUS 20 mg Lenvatinib (Lenva) orally once daily (QD) on Days 1 and 22 of a 42-day cycle (Q6W). Participants continued study intervention until progressive disease or discontinuation.","id":"FG000","title":"Pembrolizumab + Lenvatinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Screen Failure"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"78"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"80"}],"type":"Participants Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"160"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"158"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"Second Course Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"160"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Per protocol, six participants who experienced progression of Renal Cell Carcinoma (RCC) by radiographic evaluation continued second course treatment.","recruitmentDetails":"This study was conducted at 56 centers in 14 countries."}